BIOAGE LABS, INC. (BIOA) Current Ratio
- Current ratio · latest quarter: Value 17.19×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 17.19× | Current assets / current liabilities. $330.31M ÷ $19.22M ≈ 17.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 330.31M USD | Assets, Current |
| Current obligations | 19.22M USD | Liabilities, Current |
| Cash and equivalents | 73.96M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 244.78M USD | Marketable Securities, Current |
| Customer receivables | 625.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 5.65M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $330.31M | $19.22M | $73.96M | $244.78M | $625.00K | (m) | $5.65M | $0.00 | 17.19× |
| 2026-03-31 | $391.86M | $15.83M | $241.78M | $141.42M | $709.00K | (m) | $3.07M | $1.16M | 24.76× |
| 2025-12-31 | $286.79M | $20.14M | $188.89M | $92.21M | $769.00K | (m) | $2.67M | $2.65M | 14.24× |
| 2025-09-30 | $290.83M | $24.49M | $215.57M | $70.20M | $515.00K | (m) | $5.02M | $4.13M | 11.87× |
| 2025-06-30 | $301.70M | $22.84M | $220.33M | $76.97M | $603.00K | (m) | $1.33M | $5.60M | 13.21× |
| 2025-03-31 | $324.81M | $23.74M | $257.49M | $63.03M | $361.00K | (m) | $3.99M | $6.00M | 13.68× |
| 2024-12-31 | $357.10M | $27.77M | $354.35M | $0.00 | $0.00 | (m) | $2.00M | $6.00M | 12.86× |
| 2024-09-30 | $336.47M | $19.08M | $334.47M | (m) | (m) | (m) | $2.10M | $6.00M | 17.63× |
| 2023-12-31 | $25.31M | $58.17M | $21.64M | (m) | (m) | (m) | $1.87M | $6.00M | 0.44× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |